Navigation Links
Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
Date:6/30/2011

CHADDS FORD, Pa., June 30, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points. The company is currently completing additional analyses of the data and evaluating the path forward for the program.

The study was a randomized, double blind, two-arm, placebo-controlled, parallel group design and included 236 patients with moderate to severe chronic low back pain. Axomadol was orally administered at doses ranging from 100 mg/day to 300 mg/day over a four-week period with a 12-week maintenance phase. The primary outcome measure was change in average pain intensity using a Numerical Rating Scale (NRS) from baseline to final week of treatment for all patients receiving at least one dose of study drug.  

Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.

About Endo Pharmaceuticals

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, Inc., HealthTronics, Inc. and
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
2. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™
3. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
4. diaDexus Preannounces Strong Second Quarter Revenues
5. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
6. UBM Canon Announces New Japanese-Language Website for Japan Medical Design & Manufacturing Technology: www.jmdmt.com
7. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
8. Suneva Medical Announces Canadian Approval of Bellafill™
9. McNeil Consumer Healthcare Announces Voluntary Recall of One Product Lot of TYLENOL® Extra Strength Caplets 225 Count Distributed in the U.S.
10. Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team
11. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and ... entered into non-exclusive Development Agreements with Dexcom, Inc. ... insulin pumps with the Dexcom G5 and G6 ... Tandem,s next generation pump platform with Dexcom,s future ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... announced that,leading Agendia and the Netherlands Cancer Institute ... 2008 San Antonio Breast Cancer Symposium,(SABCS) and Agendia ... in Individualized Breast Cancer Therapy symposium. The San ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to ... cosmetic experts gathered to see if they could reach a consensus on the steps ... augmentation and facelifts. Overall, the group reached 90 percent consensus on a series of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic ... potential patients alike on various plastic surgery procedures including, but not limited to, ... popular dermatology procedures like Botox and fillers. , Staying up to date ...
(Date:7/31/2015)... ... 31, 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved ... percent year-over-year for the first six months ended June 30, 2015 compared with the ... beat last year’s record-revenue mark of $10.4 million. , “We know what our customers ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia ... Georgia through the Girl Scout "Be a Friend First" program. Representatives from Peach State ... , “Peach State Health Plan and our parent company, Centene Corporation, are dedicated ...
Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... ... , ... TN (PRWEB) February 3, 2010 -- King Pharmaceuticals, Inc. (NYSE:KG) today launched PainBalance, ... to healthcare professionals and others, helping them provide optimal, appropriate care for all ...
... ... in Proper Context , ... Francisco, CA (PRWEB) February 3, 2010 -- The Medpedia Project today announced Medpedia Clinical Trials, ... that are in process or about to begin. Other online sources already allow for searching ...
... ... ... College of Osteopathic Medicine (NYCOM) and School of Health Professions, in partnership with the Nassau ... campus Sports Complex. The free vaccine will be available for all members of the NYIT ...
... , NORCROSS, ... , U.S. Speedskating  Olympic team sports psychologist and sports psychology instructor for ... Colbert Report ,  yesterday, February 1st, 2010 . , Host ... aired several TV segments highlighting his many attempts to ,make the team,. ...
... found , TUESDAY, Feb. 2 (HealthDay News) -- Extended use ... able to kick the habit and reduces the risk that ... The study included 568 adults who smoked 10 or more ... smokers who used nicotine patches for the entire 24 weeks ...
... NASHVILLE, Tenn. , Feb. 2 Healthcare Realty ... stock cash dividend for the quarter ended December 31, 2009 ... share, is payable on March 4, 2010 to shareholders ... Realty Trust is a real estate investment trust that integrates owning, ...
Cached Medicine News:Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 2Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 3Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 4Health News:Medpedia Launches New Clinical Trial Platform 2Health News:Medpedia Launches New Clinical Trial Platform 3Health News:Medpedia Launches New Clinical Trial Platform 4Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 2Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 3Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 4Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 5Health News:Using Nicotine Patch Longer Boosts Efforts to Quit 2Health News:Healthcare Realty Trust Announces Fourth Quarter Dividend 2
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
The Pedia-Trake® is designed to reduce the possibility of over penetration., ,Pedia-Trake® is used to establish an emergency airway in pediatric patients more than one year old....
Medicine Products: